查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417743

GLP-1 受体促效剂市场报告：2030 年趋势、预测与竞争分析

Glucagon-Like Peptide 1 Agonists Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

GLP-1受体促效剂的趋势与预测

预计到 2030 年，GLP-1 受体促效剂的全球市场将达到约 251 亿美元，2024 年至 2030 年的复合年增长率为 6.0%。这个市场的主要驱动因素是第2型糖尿病、肥胖及相关疾病病例的增加、对不健康生活方式的适应程度的增加、糖尿病疾病的遗传史以及人口老化的增加。 GLP-1受体促效剂的全球市场前景广阔，医院和专科诊所市场充满机会。

GLP-1 受体促效剂市场洞察

Lucintel 预测，由于肥胖率增加和第 2 型糖尿病遗传风险因素增加，Dulaglutide在预测期内仍将是最大的细分市场。

由于研发的扩大和医疗设施的增加，北美在预测期内将继续成为最大的地区。

常问问题

Q1.市场规模有多大？

A1.到2030年，GLP-1受体促效剂的全球市场预计将达到251亿美元。

Q2.市场成长预测如何？

A2. 2024年至2030年，GLP-1受体促效剂的全球市场预计将以6.0%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 此市场的主要驱动因素是第2型糖尿病、肥胖及相关疾病病例的增加、对不健康生活方式的适应程度的增加、糖尿病疾病的遗传史以及人口老化的增加。

Q4.市场的主要细分市场是什么？

A4.GLP-1受体促效剂全球市场前景广阔，为医院和专科诊所提供市场机会。

Q5. 市场上主要企业有哪些？

A5.促效剂的主要企业如下。

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，由于肥胖率增加和 2 型糖尿病遗传风险因素增加，Dulaglutide在预测期内仍将是其最大的细分市场。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于研发扩张和医疗设施增加，北美在预测期内将继续成为最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球 GLP-1 受体促效剂市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球GLP-1受体促效剂市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类型分類的全球 GLP-1 受体促效剂市场
    • Exenatide
    • Liraglutide
    • Lixisenatide
    • Dulaglutide
  • 全球 GLP-1 受体促效剂市场（依品牌）
    • 拜埃塔
    • 比杜隆
    • 维克托扎
    • 特鲁利西蒂
    • 里克斯米尔
  • 依给药途径的全球 GLP-1 受体促效剂市场
    • 口服
    • 胃肠外的
    • 其他的
  • 以最终用途分類的全球 GLP-1 受体促效剂市场
    • 医院
    • 专科诊所
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球GLP-1受体促效剂市场区域分布
  • 北美GLP-1受体促效剂市场
  • 欧洲GLP-1受体促效剂市场
  • 亚太GLP-1受体促效剂市场
  • 其他地区GLP-1受体促效剂市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按药物类型分類的全球 GLP-1 受体促效剂市场成长机会
    • 全球 GLP-1 受体促效剂市场成长机会（按品牌）
    • 按途径分類的全球 GLP-1 受体促效剂市场成长机会
    • 全球 GLP-1 受体促效剂市场成长机会（依最终用途）
    • 全球 GLP-1 受体促效剂市场成长机会（按地区）
  • 全球GLP-1受体促效剂市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球 GLP-1 受体促效剂市场产能扩张
    • 全球GLP-1受体促效剂市场的併购与合资企业
    • 认证和许可

第七章主要企业概况

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan
简介目录

Glucagon-Like Peptide 1 Agonists Trends and Forecast

The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets. The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

A more than 150-page report is developed to help in your business decisions.

Glucagon-Like Peptide 1 Agonists by Segment

The study includes a forecast for the global glucagon-like peptide 1 agonists by drug type, brand, route of administration, end use, and region.

Glucagon-Like Peptide 1 Agonists Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Exenatide
  • Liraglutide
  • Lixisenatide
  • Dulaglutide

Glucagon-Like Peptide 1 Agonists Market by Brand [Shipment Analysis by Value from 2018 to 2030]:

  • Byetta
  • Bydureon
  • Victoza
  • Trulicity
  • Lyxumia

Glucagon-Like Peptide 1 Agonists Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral
  • Others

Glucagon-Like Peptide 1 Agonists Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Others

Glucagon-Like Peptide 1 Agonists Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Glucagon-Like Peptide 1 Agonists Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glucagon-like peptide 1 agonists companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glucagon-like peptide 1 agonists companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Glucagon-Like Peptide 1 Agonists Market Insights

Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Features of the Global Glucagon-Like Peptide 1 Agonists Market

Market Size Estimates: Glucagon-like peptide 1 agonists market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glucagon-like peptide 1 agonists market size by various segments, such as by drug type, brand, route of administration, end use, and region in terms of value ($B).

Regional Analysis: Glucagon-like peptide 1 agonists market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, brand, route of administration, end use, and regions for the glucagon-like peptide 1 agonists market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glucagon-like peptide 1 agonists market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the glucagon-like peptide 1 agonists market size?

Answer: The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030.

Q2. What is the growth forecast for glucagon-like peptide 1 agonists market?

Answer: The global glucagon-like peptide 1 agonists market is expected to grow with a CAGR of 6.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glucagon-like peptide 1 agonists market?

Answer: The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

Q4. What are the major segments for glucagon-like peptide 1 agonists market?

Answer: The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets.

Q5. Who are the key glucagon-like peptide 1 agonists market companies?

Answer: Some of the key glucagon-like peptide 1 agonists companies are as follows.

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Q6. Which glucagon-like peptide 1 agonists market segment will be the largest in future?

Answer: Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

Q7. In glucagon-like peptide 1 agonists market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the glucagon-like peptide 1 agonists market by drug type (exenatide, liraglutide, lixisenatide, and dulaglutide), brand (byetta, bydureon, victoza, trulicity, and lyxumia), route of administration (oral, parenteral, and others), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Glucagon-Like Peptide 1 Agonists Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Glucagon-Like Peptide 1 Agonists Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
    • 3.3.1: Exenatide
    • 3.3.2: Liraglutide
    • 3.3.3: Lixisenatide
    • 3.3.4: Dulaglutide
  • 3.4: Global Glucagon-Like Peptide 1 Agonists Market by Brand
    • 3.4.1: Byetta
    • 3.4.2: Bydureon
    • 3.4.3: Victoza
    • 3.4.4: Trulicity
    • 3.4.5: Lyxumia
  • 3.5: Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
    • 3.5.1: Oral
    • 3.5.2: Parenteral
    • 3.5.3: Others
  • 3.6: Global Glucagon-Like Peptide 1 Agonists Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Glucagon-Like Peptide 1 Agonists Market by Region
  • 4.2: North American Glucagon-Like Peptide 1 Agonists Market
    • 4.2.2: North American Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.3: European Glucagon-Like Peptide 1 Agonists Market
    • 4.3.1: European Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.3.2: European Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.4: APAC Glucagon-Like Peptide 1 Agonists Market
    • 4.4.1: APAC Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.4.2: APAC Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.5: ROW Glucagon-Like Peptide 1 Agonists Market
    • 4.5.1: ROW Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.5.2: ROW Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Brand
    • 6.1.3: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
    • 6.1.4: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by End Use
    • 6.1.5: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Region
  • 6.2: Emerging Trends in the Global Glucagon-Like Peptide 1 Agonists Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Glucagon-Like Peptide 1 Agonists Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glucagon-Like Peptide 1 Agonists Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Bristol-Myers Squibb Company
  • 7.3: AstraZeneca
  • 7.4: Pfizer
  • 7.5: Baxter
  • 7.6: Hikma Pharmaceuticals
  • 7.7: Amneal Pharmaceuticals
  • 7.8: Teva Pharmaceuticals
  • 7.9: Sun Pharmaceuticals
  • 7.10: Mylan